key: cord-0771432-0x9p5nh2
authors: Tauzin, A.; Gong, S. Y.; Painter, M. M.; Goel, R. R.; Chatterjee, D.; Beaudoin-Bussieres, G.; Marchitto, L.; Boutin, M.; Laumaea, A.; Okeny, J.; Gendron-Lepage, G.; Bourassa, C.; Medjahed, H.; Goyette, G.; Williams, J. C.; Bo, Y.; Gokool, L.; Morrisseau, C.; Arlotto, P.; Bazin, R.; Fafard, J.; Tremblay, C.; Kaufmann, D. E.; De Serres, G.; Cote, M.; Duerr, R.; Martel-Laferriere, V.; Greenplate, A. R.; Wherry, E. J.; Finzi, A.
title: A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses
date: 2022-04-18
journal: nan
DOI: 10.1101/2022.04.18.22273967
sha: a17a00d256010d218340e07981967622fc164ba1
doc_id: 771432
cord_uid: 0x9p5nh2

Due to the recrudescence of SARS-CoV-2 infections worldwide, mainly caused by Omicron BA.1 and BA.2 variants of concern, several jurisdictions are administering a mRNA vaccine boost. Here, we analyzed humoral responses induced after the second and third doses of mRNA vaccine in naive and previously-infected donors who received their second dose with an extended 16-week interval. We observed that the extended interval elicited robust humoral responses against VOCs, but this response was significantly diminished 4 months after the second dose. Administering a boost to these individuals brought back the humoral responses to the same levels obtained after the extended second dose. Interestingly, we observed that administering a boost to individuals that initially received a short 3-4 weeks regimen elicited humoral responses similar to those elicited in the long interval regimen. Nevertheless, humoral responses elicited by the boost in naive individuals did not reach those present in previously-infected vaccinated individuals.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 18, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 18, 2022. ; https://doi.org/10.1101/2022.04.18.22273967 doi: medRxiv preprint

We evaluated the ability of plasma IgG to recognize SARS-CoV-2 full-length S variants 106 after the second and the third dose of vaccine (Figure 1 C-G). After the second dose, plasma from 107 naïve donors recognized the D614G S less efficiently than plasma from PI individuals ( Figure 1C) . 108

Four months after the second dose (V4), we observed a decreased recognition for both groups, 109 but more pronounced in the naïve group. The third dose (V5) increased D614G S recognition by 110 the naïve group, reaching levels similar to those achieved after the second dose (V3) ( Figure 1C ). 111

However, even after the boost, the level of recognition in naïve donors did not reach the same 112 level as in the PI group. 113

The original Wuhan strain was used to develop mRNA SARS-CoV-2 vaccines. Numerous 114 mutations, particularly in the S glycoprotein, reduced the ability of vaccine-induced Abs to 115 recognize currently circulating strains. We tested the S recognition of several VOCs in circulation 116 after mRNA vaccination ( Figure 1D -G, S2C-E). For all the VOCs S tested, a similar pattern of 117 response than for D614G S was observed. Except for Omicron and BA.1.1 S at V5, plasma from 118 PI donors more efficiently recognized S variants than naïve donors at all time points. Again, 119

booster-elicited antibodies able to recognize the different S glycoproteins reached levels similar 120 as those obtained after the second dose ( Figure 1D -G). Comparable responses were observed 121 when we measured the capacity of plasma to recognize the S2 subunit ( Figure S1A ). 122

We also evaluated whether the booster impacted the capacity of plasma to recognize the 123 S glycoprotein of the endemic HKU1 human Betacoronaviruses ( Figure S1B ). We did not observe 124 major changes in recognition after the second and third doses. However, for all time points plasma 125 from PI donors always recognized better the HCoV-HKU1 S than the naïve group. This suggests 126 that natural infection elicits more cross-reactive antibodies. 127 128 129 130 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

We evaluated functional activities of vaccine-elicited Abs after the second and third doses 132 ( Figure 2 ). We measured Fc-effector functions using a well-described antibody-dependent cellular 133 cytotoxicity (ADCC) assay (Anand et Figure 2A ). We noted that while ADCC remained relatively stable over time for PI individuals, it 137 significantly decreased 4 months after the second dose for naïve individuals (V4). A similar pattern 138 of responses was observed for the neutralizing activity against pseudoviruses carrying the D614G 139 S ( Figure 2B ). At the three time points, the neutralizing activity was better in the PI group 140 compared to naïve group. The level of neutralizing Abs remained stable in PI individuals whereas 141 it significantly decreased in naïve donors at V4 but was significantly increased by the boost. 142

When looking at the neutralizing activity against VOCs, we observed that plasma from PI 143 group more efficiently neutralized all pseudoviruses than the naïve group after the second dose 144 individuals, the integrated network was less dense after the second dose compared to naïve 155 donors ( Figure 3B ), suggesting a less focused immune response possibly due to the 156 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. However, whether the humoral advantages observed with the long interval persist after the boost 167 remains unclear. To address this important question, we measured longitudinally the level of anti-168 RBD IgG in cohorts of naïve and PI individuals that received their first two doses with the standard 169 (short interval, SI) or the extended regimen (long interval, LI). Basic demographic characteristics 170 of the cohorts and detailed vaccination time points are summarized in Table 2 and Figure 4A . 171

Collection time points did not perfectly match between the two cohorts rendering perilous a side-172 by-side comparison using assays that only measure antibody quantities rather than their quality. 173

We therefore decided to measure the avidity for the RBD of the induced IgG by a previously 174 described assay (Björkman et al., 1999; Fialová et al., 2017; Tauzin et al., 2022b) . This assay 175

consists of parallel ELISAs with washing buffer having or not a chaotropic agent (8M urea). The 176 RBD-avidity index therefore becomes a surrogate of antibody maturation since only Abs with the 177 highest avidity remain attached to the RBD after 8M urea washing ( Figure S3 ). 178

Anti-RBD antibodies reached their peak level faster with the SI compared to the LI in naïve 179 individuals ( Figure 4B ). While antibody levels rapidly decreased after the second dose in the SI 180 regimen, the decay in the LI group was slower. In both groups, a booster elicited the highest levels 181 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 18, 2022. ; https://doi.org/10.1101/2022.04.18.22273967 doi: medRxiv preprint of antibodies. Consistent with the proposed use of the RBD-avidity index as a surrogate for 182 antibody maturation, the kinetics differed from those of the regular ELISA that only measure total 183 levels of anti-RBD Abs. For example, 12 weeks after the first dose in the LI regimen, there was a 184 significant decline in anti-RBD IgG levels but the affinity of anti-RBD Abs likely improved as shown 185 by an increase in their avidity ( Figure 4B and D), consistent with recent results (Tauzin et al., 186 2022b) . We previously reported that several humoral responses, including RBD-avidity was lower 187 in individuals receiving a SI (Tauzin et al., CHM 2022) . However, whether this difference remained 188 after the boost was unknown. Here we report that the boost brought the RBD-avidity index to the 189 same level, independent of the vaccine regimen, suggesting that the boost is required to further 190 improve antibody responses in naïve individuals that received the SI regimen ( Figure 4D ). 191

For the PI groups, the SI and LI led rapidly to high levels of IgG ( Figure 4C ). These levels 192 slightly decreased over time, however they remained more stable in the LI group, likely due to the 193 delayed dose. After the boost, we observed similar levels of IgG in both groups. Regarding the 194 avidity, the SI rapidly led to IgG with strong avidity which remained stable over time with only a 195 minor effect induced by the boost ( Figure 4E ). For the LI group, the first dose increased the avidity, 196 but to a lower extend than in the SI group. The second dose boosted the avidity to the same level 197 than in the SI group. As observed in the SI group, the boost did not improve the avidity, indicating 198 that individuals that developed hybrid immunity due to natural infection already had a higher 199 antibody avidity than naïve vaccinated individuals. 200 201 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Antibody maturation is a complex process that takes place in the germinal center (Young 219 and Brink, 2021). This process is important for vaccine efficacy since it allows the immune system 220 to generate antibodies with greater potency for viral neutralization and Fc-effector functions. We 221 recently developed a high-throughput assay that could be used as a surrogate for antibody 222 maturation (Tauzin et al., 2022b) . Using this assay, we observed that the avidity of anti-RBD Abs 223 was significantly higher in the LI after the second dose compared to the SI, suggesting that 224 increasing the time between exposure to the antigen led to a better maturation of the B cells and 225 so to Abs with higher avidity (Tauzin et al., 2022a) . Here we report that a boost allows the SI 226 group to elicit Abs with the same avidity as in the LI group. Since the RBD is highly immunogenic, 227 it is possible that humoral responses against this domain compromise responses against less 228 immunogenic domains of the Spike. Thus, in future studies it would be interesting to measure 229 the evolution of the avidity against other Spike domains. The third dose of SARS-CoV-2 mRNA vaccine led to high levels of humoral responses 249 against VOCs, irrespective of the interval between the two first doses. We do not yet know about 250 the durability of this immunity but epidemiological studies have shown a decline in vaccine 251 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 18, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 18, 2022. Soros Fellowship for New Americans (to R.R.G). The funders had no role in study design, data 284 collection and analysis, decision to publish, or preparation of the manuscript. We declare no 285 competing interests. 286 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 18, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The study was conducted in 20 SARS-CoV-2 naïve individuals (8 males and 12 females; age 406 range: 33-64 years) and 11 SARS-CoV-2 previously-infected individuals (8 males and 3 females; Horseradish peroxidase (HRP)-conjugated Abs able to detect the Fc region of human IgG 426 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 18, 2022. [TBS] containing 0.1% Tween20). CR3022 mAb (50 ng/ml) or a 1/500 dilution of plasma were 471 prepared in a diluted solution of blocking buffer (0.1 % BSA) and incubated with the RBD-coated 472 wells for 90 minutes at room temperature. Plates were washed four times with washing buffer 473 followed by incubation with secondary Abs (diluted in a diluted solution of blocking buffer (0.4% 474 BSA)) for 1h at room temperature, followed by four washes. To calculate the RBD-avidity index, 475 we performed in parallel a stringent ELISA, where the plates were washed with a chaotropic 476 agent, 8M of urea, added of the washing buffer. This assay was previously described (Tauzin et 477 al., 2022b) . HRP enzyme activity was determined after the addition of a 1:1 mix of Western 478 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 18, 2022. ; https://doi.org/10.1101/2022.04.18.22273967 doi: medRxiv preprint tagged full length SARS-CoV-2 S (CEM.NKr.SARS-CoV-2.Spike cells). These cells were stained 505 for viability (AquaVivid; Thermo Fisher Scientific, Waltham, MA, USA) and cellular dyes (cell 506 proliferation dye eFluor670; Thermo Fisher Scientific) to be used as target cells. Overnight rested 507

PBMCs were stained with another cellular marker (cell proliferation dye eFluor450; Thermo Fisher 508 Scientific) and used as effector cells. Stained target and effector cells were mixed at a ratio of 509 1:10 in 96-well V-bottom plates. Plasma (1/500 dilution) or monoclonal antibody CR3022 (1 510 µg/mL) were added to the appropriate wells. The plates were subsequently centrifuged for 1 min 511 at 300g, and incubated at 37°C, 5% CO2 for 5 hours before being fixed in a 2% PBS-formaldehyde 512 solution. ADCC activity was calculated using the formula: [(% of GFP+ cells in Targets plus 513

Targets) x 100 by gating on transduced live target cells. All samples were acquired on an LSRII 515 cytometer (BD Biosciences) and data analysis was performed using FlowJo v10.7.1 (Tree Star). 516

The specificity threshold was established using the following formula: mean of pre-pandemic 517 SARS-CoV-2 negative plasma + (3 standard deviation of the mean of pre-pandemic SARS-CoV-518 2 negative plasma). 519 520

To produce the pseudoviruses, 293T cells were transfected with the lentiviral vector pNL4.3 R-E-522

Luc (NIH AIDS Reagent Program) and a plasmid encoding for the indicated S glycoprotein 523 (D614G, Delta and Omicron, BA.1.1 and BA.2) at a ratio of 10:1. Two days post-transfection, cell 524 supernatants were harvested and stored at -80°C until use. For the neutralization assay, 293T-525 ACE2 target cells were seeded at a density of 1×10 4 cells/well in 96-well luminometer-compatible 526 tissue culture plates (Perkin Elmer) 24h before infection. Pseudoviral particles were incubated 527 with several plasma dilutions (1/50; 1/250; 1/1250; 1/6250; 1/31250) for 1h at 37°C and were then 528 added to the target cells followed by incubation for 48h at 37°C. Then, cells were lysed by the 529 addition of 30 µL of passive lysis buffer (Promega) followed by one freeze-thaw cycle. An LB942 530 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 18, 2022. and this information was used to apply the appropriate (parametric or nonparametric) statistical 542 test. Differences in responses for the same patient before and after vaccination were performed 543 using Wilcoxon tests. Differences in responses between naïve and PI individuals at each time 544 point (V3, V4 and V5) were measured by Mann-Whitney tests. Differences in responses against 545 the different S for the same patient were measured by Friedman tests. P values < 0.05 were 546 considered significant; significance values are indicated as * p < 0.05, * * p < 0.01, * * * p < 0.001, 547 * * * * p < 0.0001. Spearman's R correlation coefficient was applied for correlations. Statistical tests 548 were two-sided and p < 0.05 was considered significant. 549 550

Edge bundling graphs were generated in undirected mode in R and RStudio using ggraph, igraph, 552 tidyverse,and RColorBrewer packages (R Core Team, 2014). Edges are only shown if p < 0.05, 553 and nodes are sized according to the connecting edges' r values. Nodes are color-coded 554 according to groups of parameters. 555 556 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Error bars indicate means ± SEM. (* P < 0.05; ** P < 0.01; *** P < 0.001; **** P < 0.0001; ns, non-significant). For naïve donors, n=20 and for previously infected donors n=11. Edge bundling correlation plots where red and blue edges represent positive and negative correlations between connected parameters, respectively. Only significant correlations (p < 0.05, Spearman rank test) are displayed. Nodes are color coded based on the grouping of parameters according to the legend. Node size corresponds to the degree of relatedness of correlations. Edge bundling plots are shown for correlation analyses using two different datasets; i.e., SARS-CoV-2 naïve individuals vaccinated with the short interval at V3 and V5 respectively. n=20. Error bars indicate means ± SEM (*p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns, non-significant). n = 20.

Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against 601 COVID-19-Associated Emergency Department and Urgent Care Encounters and 602 Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance -603 VISION Network, 10 States

Comparison of different enzyme-linked 606 immunosorbent assay methods for avidity determination of antiphospholipid antibodies

Distinct antibody and memory B cell 610 responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination

Contribution of single mutations to selected 614 SARS-CoV-2 emerging variants spike antigenicity

mRNA booster immunization elicits potent neutralizing serum 618 activity against the SARS-CoV-2 Omicron variant

Isolation and characterization of cross-622 neutralizing coronavirus antibodies from COVID-19+ subjects

Omicron (BA.1) and Sub-Variants 625 (BA.1, BA.2 and BA.3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative 626 Sequence and Structural-based Computational Assessment

Structural basis and mode of action for two broadly neutralizing 630 antibodies against SARS-CoV-2 emerging variants of concern

Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants

Vaccination-infection interval determines cross-neutralization 638 potency to SARS-CoV-2 Omicron after breakthrough infection by other variants

Temporal associations of B and T cell immunity 642 with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen

Third BNT162b2 Vaccination Neutralization of 646 SARS-CoV-2 Omicron Infection

Immunogenicity of standard and extended 650 dosing intervals of BNT162b2 mRNA vaccine

Cross-Sectional Evaluation of Humoral 654 Responses against SARS-CoV-2 Spike

R: A language and environment for statistical computing. R Foundation for 657 Statistical Computing

A single dose of the SARS-CoV-2 vaccine 663 BNT162b2 elicits Fc-mediated antibody effector functions and T cell responses

Strong humoral immune responses 667 against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between 668 doses

Evolution of Anti-RBD IgG Avidity 671 Following SARS-CoV-2 Infection

Live imaging of SARS-CoV-2 infection in mice 674 reveals that neutralizing antibodies require Fc function for optimal efficacy

Rapid epidemic expansion of the SARS-CoV-678 2 Omicron variant in southern Africa. Nature 1-10

Tracking SARS-CoV-2 variants

CoV-2-variants

Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard 682 With Vaccination Data

The unique biology of germinal center B cells

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity